Novel Platform Development

We don't just run assays. We build the ones that don't exist yet.

An R&D partner for pharmaceutical companies, academic researchers, and industry collaborators who need validated screening capability built for targets where no established assay currently exists.

What this is

R&D partnerships for targets that need a new approach.

Antiparasitic drug discovery increasingly requires screening capability for targets outside the traditional catalog. Building validated assays for these takes deep parasitology expertise, live parasite material, and proper infrastructure.

ADR Solutions works with partners to design, develop, and validate novel in vitro screening platforms, with milestone-based delivery structures suited to pharma and industry timelines. This is not a catalog service. Every project is scoped individually. If you have a target and need a validated assay, we'd like to talk.

Pharma & biotech

Drug discovery programs that need validated screening infrastructure for antiparasitic targets where no established assay exists.

Academic researchers

Groups studying new parasite targets or resistance mechanisms who need assay development support and access to live parasite material.

Industry collaborators

Animal health companies and research organizations looking for a scientific partner to co-develop screening capability.

Current development

Platforms in active development.

These platforms are currently in development. Don't see your target? We evaluate new platform development projects on a case-by-case basis. We're interested in understanding the problem before committing to whether we can solve it.

In development

Ctenocephalides felis — adult flea assay

An in vitro motility assay for adult cat fleas — an ectoparasite target with significant commercial relevance in companion animal health, for which validated screening platforms are limited. Tarsal and sensory assay formats in development.

In development

Ancylostoma caninum — drug resistance assay

A targeted assay for detecting and characterizing anthelmintic resistance in canine hookworm — an emerging and serious concern in companion animal medicine with increasing relevance for drug efficacy research.

How we work together

What a collaboration looks like.

Discovery conversation

We discuss your target, your program needs, and what a validated assay would need to deliver. No commitment required at this stage.

Scoping & proposal

We develop a technical proposal with defined milestones, deliverables, and timeline. IP arrangements discussed at this stage.

Development & validation

We build and validate the platform with regular milestone check-ins. All work performed under confidentiality agreement.

Delivery & handoff

Validated platform delivered with full documentation. Ongoing screening services available once the platform is established.

In vivo study support is available for partners with appropriate needs. Contact us directly to discuss.

Have a target that needs a new assay?

We're interested in the problem before we commit to the solution. Let's start with a conversation.

Start a conversation →